Shots:
- The EC has approved Rxulti (brexpiprazole) to treat schizophrenia in pts (≥13yrs.) following CHMP’s positive opinion in Jan 2025
- Approval was based on P-III trial assessing Rxulti (2 to 4mg/day, PO, QD) vs PBO vs Aripiprazole in adolescents (n=316) for 6wks. that showed greater reduction in symptom severity compared to PBO as measured by PANSS total score
- Rxulti modulates serotonin & dopamine systems, combining partial agonist activity at 5-HT1A & D2 receptors with antagonist activity at 5-HT2A receptors. It also antagonizes noradrenergic α1B/2C receptors within the sub-nanomolar Ki range
Ref: Bussineswire | Image: Otsuka and Lundbeck
Related News:- Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
